# EDGAR Filing Document

**Accession Number:** 0001374339
**File Stem:** 0001104659-25-121627
**Filing Date:** 2025-12
**Character Count:** 5682
**Document Hash:** 94d3edac1ef1279ce84e6812057158ca
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-121627.hdr.sgml**: 20251216

**ACCESSION NUMBER**: 0001104659-25-121627

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251212

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20251216

**DATE AS OF CHANGE**: 20251216

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ProMIS Neurosciences Inc.
- **CENTRAL INDEX KEY:** 0001374339
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41429
- **FILM NUMBER:** 251576138

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 200, 1920 YONGE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4S 3E2
- **BUSINESS PHONE:** 416-847-6898

**MAIL ADDRESS:**
- **STREET 1:** SUITE 200, 1920 YONGE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4S 3E2

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMORFIX LIFE SCIENCES LTD
- **DATE OF NAME CHANGE:** 20060831

?xml version='1.0' encoding='ASCII'? PROMIS NEUROSCIENCES INC._December 12, 2025

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 12, 2025**

## PROMIS NEUROSCIENCES INC.
**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Ontario, Canada** | **001-41429** | **98-0647155** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

---

| | |
|:---|:---|
| **Suite 200, 1920 Yonge Street,** <br>**Toronto, Ontario** | **M4S 3E2** |
| **(Address of principal executive**<br>**offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (416) 847-6898**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on Which Registered** |
| Common Shares, no par value per share | PMN | The NASDAQ Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 8.01 Other Events.**

On December 12, 2025, ProMIS Neurosciences Inc. (the "Company") received a written notification from the Nasdaq Stock Market Listing Qualifications Staff indicating that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market ("Nasdaq") pursuant to NASDAQ Listing Rule 5550(a)(2) ("Bid Price Rule") and that the matter is now closed.

As previously disclosed, on January 8, 2025, the Company received a deficiency letter from Nasdaq notifying the Company that, for the 30 consecutive business days prior to the date of the deficiency letter, the closing bid price for the Company's common stock was trading below the minimum $1.00 per share requirement for continued inclusion on Nasdaq pursuant tothe Bid Price Rule. In accordance with Nasdaq rules, the Company was provided with an initial period of 180 calendar days, or until July 2, 2025, to regain compliance with the Bid Price Rule.

Subsequently, the Company was granted an additional 180-day grace period, until December 29, 2025, to regain compliance with the Bid Price Rule. Nasdaq's determination was based on the Company meeting the continued listing requirement for stockholder's equity and all other initial listing standards for Nasdaq with the exception of the Bid Price Rule, and the Company's provided written notice of its confirmation to cure the deficiency during the additional compliance period, including by effecting a reverse stock split, if necessary.

The closing bid price of the Company's common shares has been $1.00 or greater for the 10 consecutive business days from November 28, 2025 to December 11, 2025. Accordingly, the Company has regained compliance with the Bid Price Rule.

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **PROMIS NEUROSCIENCES INC.** | **PROMIS NEUROSCIENCES INC.** |
| Date: December 16, 2025 | By: | /s/ Neil Warma |
|  |  | Name: Neil Warma |
|  |  | Title: Chief Executive Officer |

---